FIT Biotech Oy
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FIT Biotech Oy
The latest Ebola epidemic, which the WHO says has now claimed more than 9,600 lives, has focused attention on the long-term need for a prophylactic vaccine to prevent future outbreaks of this size.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Over the past five years, big cap device companies have been some of the strongest performers among all life science stocks, and this year's conference represented something of a renaissance of device companies. However, most interesting wasn't so much the revival of interest in device stocks itself, but the message that device companies sent and that investors are embracing: "Forget about the hype; slow and steady wins the race."
- Gene Therapy, Cell Therapy